 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
6 February 2001 | Volume 134 Issue 3 | Pages 203-207
Background: Despite demonstrated benefits, intensive insulin therapy has not gained widespread clinical acceptance for several reasons: Multiple daily injections are inconvenient, adherence is a concern, and the time-activity profile may not mimic normal insulin secretion. As such, alternate means of administering insulin are being evaluated.
Objective: To assess the efficacy and safety of pulmonary delivery of insulin in type 2 diabetic patients who require insulin.
Design: Randomized, open-label, 3-month study consisting of a screening visit, a 4-week baseline lead-in phase, and a 12-week treatment phase.
Setting: General clinical research center and outpatient research clinics.
Patients: 26 patients (16 men, 10 women) with type 2 diabetes (average age, 51.1 years; average duration of diabetes, 11.2 years).
Intervention: Patients received inhaled insulin before each meal plus a bedtime injection of ultralente insulin, performed home glucose monitoring, and had weekly adjustment of insulin dose; target level for preprandial plasma glucose was 5.55 to 8.88 mmol/L (100 to 160 mg/dL).
Measurements: Glycemic control (hemoglobin A1c level) obtained at baseline and monthly for 3 months. Pulmonary function tests were done at baseline and at the end of the study.
Results: Inhaled insulin treatment for 3 months significantly improved glycemic control compared with baseline: Mean hemoglobin A1c levels decreased by 0.0071 ± 0.0072 (0.71% ± 0.72%). Patients experienced an average of 0.83 mild to moderate hypoglycemic event per month; no severe events were recorded. Patients showed no significant weight gain or change in pulmonary function compared with baseline.
Conclusions: Pulmonary delivery of insulin in type 2 diabetic patients who require insulin improved glycemic control, was well tolerated, and demonstrated no adverse pulmonary effects. Larger-scale studies are ongoing to provide long-term efficacy and safety data.
*For members of the Inhaled Insulin Study Group, see Appendix.
Author and Article Information
From University of Vermont College of Medicine, Burlington, Vermont; University of Miami Medical Center, Miami, Florida; and Pfizer Central Research, Groton, Connecticut.
Presented in abstract form as an oral presentation at the Annual Meeting of the American Diabetes Association, Chicago, Illinois, June 1998.
Acknowledgment: The authors thank Becky Aksdal for her skillful preparation of the manuscript and her valuable editorial assistance.
Grant Support: By Pfizer, Inc. Technology used for this study was licensed from Inhale Therapeutic Systems, San Carlos, California.
Requests for Single Reprints: William T. Cefalu, MD, University of Vermont College of Medicine, UHC Campus, Arnold 3433, One South Prospect Street, Burlington, VT 05401.
Current Author Addresses: Dr. Cefalu: University of Vermont College of Medicine, UHC Campus, Arnold 3433, One South Prospect Street, Burlington, VT 05401.
Dr. Skyler: University of Miami Medical Center, 1500 NW 12th Avenue, Suite 1012 East, Miami, FL 33136.
Dr. Kourides: Clinical and Scientific Affairs, Pfizer, Inc., 235 East 42nd Street, New York, NY 10017.
Drs. Landschulz and Gelfand: Department of Clinical Research, Pfizer, Inc., Eastern Point Road, Groton, CT 06340-8030.
Drs. Balagtas and Cheng: Department of Biometrics and Data Management, Pfizer, Inc., Eastern Point Road, Groton, CT 06340.
Author Contributions: Conception and design: I.A. Kourides, W.H. Landschulz, R.A. Gelfand.
Analysis and interpretation of the data: W.T. Cefalu, J.S. Skyler, I.A. Kourides, W.H. Landschulz, C.C. Balagtas, S.-L. Cheng, R.A. Gelfand.
Drafting of the article: W.T. Cefalu, I.A. Kourides, W.H. Landschulz, C.C. Balagtas, S.-L. Cheng, R.A. Gelfand.
Critical revision of the article for important intellectual content: W.T. Cefalu, J.S. Skyler, I.A. Kourides, W.H. Landschulz, C.C. Balagtas, R.A. Gelfand.
Final approval of the article: W.T. Cefalu, J.S. Skyler, I.A. Kourides, W.H. Landschulz, C.C. Balagtas, R.A. Gelfand.
Provision of study materials or patients: J.S. Skyler, W.H. Landschulz, R.A. Gelfand.
Statistical expertise: C.C. Balagtas, S.-L. Cheng.
Obtaining of funding: R.A. Gelfand.
Administrative, technical, or logistic support: W.H. Landschulz, R.A. Gelfand.
Collection and assembly of data: W.T. Cefalu, W.H. Landschulz, C.C. Balagtas, R.A. Gelfand. BRIEF COMMUNICATION
Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. B. Drummond, P. F. Schwartz, W. T. Duggan, J. G. Teeter, R. J. Riese, R. C. Ahrens, R. O. Crapo, R. D. England, N. R. MacIntyre, R. L. Jensen, et al. Intersession Variability in Single-Breath Diffusing Capacity in Diabetics without Overt Lung Disease Am. J. Respir. Crit. Care Med., August 1, 2008; 178(3): 225 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Kaparianos, E Argyropoulou, F Sampsonas, K Karkoulias, M Tsiamita, and K Spiropoulos Pulmonary complications in diabetes mellitus Chronic Respiratory Disease, May 1, 2008; 5(2): 101 - 108. [Abstract] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Exploring Treatment Strategies for Type 2 Diabetes Diabetes Care, October 1, 2007; 30(10): 2737 - 2745. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Q. Pham, H. Cohen, and V. Chu Inhaled Human [rDNA Origin] Insulin, a Novel Formulation for Diabetes Mellitus J. Clin. Pharmacol., July 1, 2007; 47(7): 890 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghosh and A. Collier Inhaled insulins Postgrad. Med. J., March 1, 2007; 83(977): 178 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. McMahon and R. A. Arky Inhaled Insulin for Diabetes Mellitus N. Engl. J. Med., February 1, 2007; 356(5): 497 - 502. [Full Text] [PDF]
|
|
|
|
 |
|
 {blacktriangledown}Exubera: inhaled insulin for diabetes DTB, January 1, 2007; 45(1): 5 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Barnett, M. Dreyer, P. Lange, M. Serdarevic-Pehar, and on behalf of the Exubera Phase III Study Group An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Glibenclamide as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on Metformin Diabetes Care, August 1, 2006; 29(8): 1818 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan, J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, and B. Zinman Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, August 1, 2006; 29(8): 1963 - 1972. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Barnett, M. Dreyer, P. Lange, M. Serdarevic-Pehar, and on behalf of the Exubera Phase III Study Group An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Metformin as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on a Sulfonylurea. Diabetes Care, June 1, 2006; 29(6): 1282 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Morton-Eggleston and E. J Barrett Inhaled insulin. BMJ, May 6, 2006; 332(7549): 1043 - 1044. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Insulin Treatment and Type 1 Diabetes Topics Diabetes Care, April 1, 2006; 29(4): 936 - 944. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Comi Treatment of Type 2 Diabetes Mellitus: A Weighty Enigma Ann Intern Med, October 18, 2005; 143(8): 609 - 610. [Full Text] [PDF]
|
|
|
|
|
|
K. M. Rave, L. Nosek, A. de la Pena, M. Seger, C. S. Ernest II, L. Heinemann, R. P. Batycky, and D. B. Muchmore Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro Diabetes Care, October 1, 2005; 28(10): 2400 - 2405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Mandal Inhaled insulin for diabetes mellitus Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1359 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rave, S. Bott, L. Heinemann, S. Sha, R. H.A. Becker, S. A. Willavize, and T. Heise Time-Action Profile of Inhaled Insulin in Comparison With Subcutaneously Injected Insulin Lispro and Regular Human Insulin Diabetes Care, May 1, 2005; 28(5): 1077 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Odegard and K. L Capoccia Inhaled Insulin: Exubera Ann. Pharmacother., May 1, 2005; 39(5): 843 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Freemantle, L. Blonde, D. Duhot, M. Hompesch, R. Eggertsen, F.D. R. Hobbs, L. Martinez, S. Ross, B. Bolinder, and E. Stridde Availability of Inhaled Insulin Promotes Greater Perceived Acceptance of Insulin Therapy in Patients With Type 2 Diabetes Diabetes Care, February 1, 2005; 28(2): 427 - 428. [Full Text] [PDF]
|
|
|
|
|
|
E. Wajcberg, Y. Miyazaki, C. Triplitt, E. Cersosimo, and R. A. DeFronzo Dose-Response Effect of a Single Administration of Oral Hexyl-Insulin Monoconjugate 2 in Healthy Nondiabetic Subjects Diabetes Care, December 1, 2004; 27(12): 2868 - 2873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Quattrin, A. Belanger, N. J.V. Bohannon, S. L. Schwartz, and for the Exubera Phase III Study Group Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin Therapy in Patients With Type 1 Diabetes: Results of a 6-month, randomized, comparative trial Diabetes Care, November 1, 2004; 27(11): 2622 - 2627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Hollander, L. Blonde, R. Rowe, A. E. Mehta, J. L. Milburn, K. S. Hershon, J.-L. Chiasson, and S. R. Levin Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin Therapy in Patients With Type 2 Diabetes: Results of a 6-month, randomized, comparative trial Diabetes Care, October 1, 2004; 27(10): 2356 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Heinemann and T. Heise Review: Current status of the development of inhaled insulin The British Journal of Diabetes & Vascular Disease, September 1, 2004; 4(5): 295 - 301. [Abstract] [PDF]
|
|
|
|
|
|
J. Rosenstock, J. C. Cappelleri, B. Bolinder, and R. A. Gerber Patient Satisfaction and Glycemic Control After 1 Year With Inhaled Insulin (Exubera) in Patients With Type 1 or Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1318 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Cherrington, D. W. Neal, D. S. Edgerton, D. Glass, L. Bowen, C. H. Hobbs, C. Leach, R. Rosskamp, and T. R. Strack Inhalation of Insulin in Dogs: Assessment of Insulin Levels and Comparison to Subcutaneous Injection Diabetes, April 1, 2004; 53(4): 877 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hermansen, T. Ronnemaa, A. H. Petersen, S. Bellaire, and U. Adamson Intensive Therapy With Inhaled Insulin via the AERx Insulin Diabetes Management System: A 12-week proof-of-concept trial in patients with type 2 diabetes Diabetes Care, January 1, 2004; 27(1): 162 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Cefalu Concept, Strategies, and Feasibility of Noninvasive Insulin Delivery Diabetes Care, January 1, 2004; 27(1): 239 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Henry, S. Mudaliar, N. Chu, D. Kim, D. Armstrong, T. T. Davis, B. An, and R. R. Reinhardt Young and Elderly Type 2 Diabetic Patients Inhaling Insulin with the AERx(R) Insulin Diabetes Management System: A Pharmacokinetic and Pharmacodynamic Comparison J. Clin. Pharmacol., November 1, 2003; 43(11): 1228 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Weiss, S.-L. Cheng, I. A. Kourides, R. A. Gelfand, and W. H. Landschulz Inhaled Insulin Provides Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Agents: A Randomized Controlled Trial Arch Intern Med, October 27, 2003; 163(19): 2277 - 2282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Gerich Clinical Significance, Pathogenesis, and Management of Postprandial Hyperglycemia Arch Intern Med, June 9, 2003; 163(11): 1306 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Henry, S. R.D. Mudaliar, W. C. Howland III, N. Chu, D. Kim, B. An, and R. R. Reinhardt Inhaled Insulin Using the AERx Insulin Diabetes Management System in Healthy and Asthmatic Subjects Diabetes Care, March 1, 2003; 26(3): 764 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lange, J. Parner, P. Schnohr, and G. Jensen Copenhagen City Heart Study: longitudinal analysis of ventilatory capacity in diabetic and nondiabetic adults Eur. Respir. J., December 1, 2002; 20(6): 1406 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan Initial Management of Glycemia in Type 2 Diabetes Mellitus N. Engl. J. Med., October 24, 2002; 347(17): 1342 - 1349. [Full Text] [PDF]
|
|
|
|
|
|
W. T. Cefalu Inhaled Insulin: A Proof-of-Concept Study Ann Intern Med, May 1, 2001; 134(9_Part_1): 795 - 795. [Full Text] [PDF]
|
|
|
|
 |
|
 Inhaled Insulin Can Improve Glycemic Control Journal Watch (General), February 13, 2001; 2001(213): 2 - 2. [Full Text]
|
|
|
|
|
|
D. M. Nathan Inhaled Insulin for Type 2 Diabetes: Solution or Distraction? Ann Intern Med, February 6, 2001; 134(3): 242 - 244. [Full Text] [PDF]
|
|
Article
